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http://dx.doi.org/10.1016/j.jmii.2013Background: To identify the clinical characteristics and risk factors for mortality of patients
with cefepime-resistant Pseudomonas aeruginosa (FRPa) bacteremia.
Methods: This retrospective study analyzed adult patients with FRPa bacteremia hospitalized
between January 2006 and December 2011.
Results: Seventy eight patients (46 male, 32 female; mean age: 72.2  14.1 years) were
included. Of them, 46 (59.0%) had ventilator use and 45 (57.7%) had intensive care unit stay.
All the bacteremia episodes were health-care associated or hospital acquired, and 55.1% of
FRPa blood isolates were multidrug resistant. The sources of bacteremia were identified in
42 patients (53.8%), with pneumonia being the most common one (28/42; 66.7%). The mean
interval between admission and the sample date of the first FRPa-positive blood culture was
45.8  52.6 days. The mean Pittsburgh bacteremia score was 5.0  3.4. The 15-day and 30-
day mortality rates were 50.0% and 65.4%, respectively. Patients (41; 52.6%) on appropriate
antibiotic therapy within 72 hours of the first FRPa-positive blood culture had a higher 30-
day survival rate than those without (48.8% vs. 18.9%, pZ 0.011 by log-rank test). Multivariate
analyses revealed that a higher Pittsburgh bacteremia score was an independent risk factor for
either 15-day (pZ 0.002) or 30-day mortality (pZ 0.010), and appropriate antibiotic therapy
within 72 hours was an independent protecting factor for either 15-day (p Z 0.049) or 30-day
mortality (p Z 0.017).nfectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, 5 Fu-
aiwan.
com (M.-H. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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176 T.-Y. Su et al.Conclusion: FRPa bacteremia had a high mortality rate. The disease severity and appropriate
antimicrobial therapy within 72 hours of positive blood culture were related to the patients’
outcome.
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Pseudomonas aeruginosa has been a leading cause of
nosocomial infections,1,2 and infections caused by P. aer-
uginosa are often life threatening.3 Emergence of antibiotic
resistance in P. aeruginosa has been increasingly re-
ported,4,5 and its impact was the increased in-hospital
mortality, cost, and hospital stay.1,6,7 Identifying effica-
cious antimicrobial options for multidrug-resistant (MDR) P.
aeruginosa is still a challenge for physicians.
Based on our computer-assisted microbiology laboratory
database from January 2006 to December 2011, the disk
diffusion antimicrobial susceptibility testing for the clinical
nonduplicated P. aeruginosa blood isolates revealed that
the drug-resistant rates to piperacillin, imipe-
nemecilastatin, ciprofloxacin, ceftazidime, cefepime, and
amikacin were 14.1%, 12.7%, 10.7%, 10.3%, 7.8%, and 2.3%,
respectively. Cefepime had the second lowest resistant
rate (7.8%), which was only second to that of amikacin
(2.3%). Therefore, cefepime has become an important
empirical treatment option for patients with suspected P.
aeruginosa infections in our clinical practice, particularly
for those with high disease severity.
Croughs et al8 had described a significant trend of
increasing cefepime resistance in P. aeruginosa from 1998
to 2010 (4.8% to 6.4%; p Z 0.016). Furthermore, Akhabue
et al9 had recognized that bacteremia caused by cefepime-
resistant P. aeruginosa (FRPa) was an independent risk
factor for in-hospital mortality. Thus, to investigate the
clinical characteristics and risk factors for mortality of FRPa
bacteremia, we conducted a retrospective study for pa-
tients with FRPa bacteremia.
Materials and methods
Setting
This retrospective study was conducted at the Chang Gung
Memorial Hospital (CGMH, Linkou branch), a 3715-bed
university-affiliated tertiary-care medical center with 308
intensive care unit (ICU) beds in northern Taiwan. This
study was approved by the Institutional Review Board of
CGMH-Linkou (number 101-0929B).
Study design and patients
Through the computer-assisted microbiology laboratory
database, patients aged  18 years and at least one blood
culture positive for FRPa admitted to our hospital between
January 2006 and December 2011 were reviewed. Cases of
FRPa bacteremia with symptoms and signs suggestive ofsystemic infection were included. The symptoms and signs
of infection included at least one of the following clinical
characteristics: (1) body temperature <36C or >38C; (2)
heart rate >90 beats per minute; (3) tachypnea >
20breaths per minute; or an arterial partial pressure of
carbon dioxide <32 mmHg; (4) white blood cell count
<4000 cells/mm3 or >12,000 cells/mm3; or the presence of
>10% immature neutrophils. For patients with multiple
episodes of FRPa bacteremia, only the first episode was
included for analysis.
Microbiology
Blood cultures were processed in the clinical microbiology
laboratory, using the automated blood culture system
(BACTEC 9240 system; Becton Dickinson Diagnostic Instru-
ment Systems, Sparks, MD, USA). P. aeruginosa isolates
were identified on the basis of the following properties:
aerobic Gram-negative bacilli on a Gram’s stain with
glucose nonfermentation, positive oxidase test, production
of blueegreen or yellowegreen fluorescent pigment, and
growth at 42C.10 Antimicrobial susceptibilities testing was
performed using the disk diffusion method according to the
Clinical and Laboratory Standards Institute (CLSI) M100-S22
criteria.11 The antibiotic disks (BD Microbiology Systems,
Cockeysville, MD, USA) for P. aeruginosa included amikacin,
gentamicin, ceftazidime, cefepime, piperacillin, piper-
acillinetazobactam, imipenem, meropenem, and cipro-
floxacin. Based on the CLSI criteria,11 nonsusceptible P.
aeruginosa isolates were those with an inhibitory zone
diameter for cefepime <18 mm, and these were classified
as FRPa in this study. MDR P. aeruginosa was defined as P.
aeruginosa with resistance to at least three of the following
four antimicrobial classes: antipseudomonal penicillins (or
cephalosporins), antipseudomonal carbapenems (including
imipenemecilastatin and meropenem), antipseudomonal
fluoroquinolones (including ciprofloxacin and levofloxacin),
and aminoglycosides. Resistance to each class was defined
as intermediate or complete resistance to at least one
agent of each class.12
Data collection and definition
Data on age, sex, comorbid diseases, image and laboratory
findings, surgical findings, antimicrobial susceptibility
testing, clinical characteristics, and outcomes of the pa-
tients with FRPa bacteremia were gathered by reviewing
the inpatient medical records. The comorbid diseases
identified were hypertension, end-stage renal disease,13
diabetes mellitus, cerebral vascular accident, liver
cirrhosis, chronic pulmonary disease, and malignancy.
Ventilator use, ICU stay, Pittsburgh bacteremia score,
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venous catheters (CVCs) on the sample date of the first
blood culture positive for FRPa were recorded. CVCs were
classified into short-term (in situ < 14 days, such as central
venous pressure or double lumen) and long-term ones (in
situ  14 days, such as Port-a-Cath or Hickman).14 The in-
tervals between admission and the sample date of the first
FRPa-positive blood culture were also recorded. Hospital-
acquired infection was defined as an infection that
occurred 48 hours after hospital admission. Severity of
illness was calculated by the Pittsburgh bacteremia score.15
A Pittsburgh bacteremia score 4 was defined as severely
ill. The severity of comorbidities was evaluated using the
Charlson Comorbidity Index for chronic diseases.16
The sources of bacteremia were determined according
to the medical records, image studies, surgical findings, and
microbiological evidence. The sources of bacteremia were
categorized into lower respiratory tract, urinary tract, skin
and soft tissue, catheter-related bloodstream infection
(CRBSI), and intra-abdominal infection. According to the
clinical practice guidelines updated by the Infectious Dis-
eases Society of America in 2009, a definitive diagnosis of
CRBSI requires that the same organism grows from at least
one percutaneous blood culture and from a culture of the
catheter tip.14 The FRPa bacteremia with multiple sources
was defined as FRPa bacteremia with at least two identified
sources. If there was no identified source, it was catego-
rized as primary FRPa bacteremia. Polymicrobial bacter-
emia was defined as one or more additional bacterial
species isolated from blood simultaneously with FRPa.
Any one agent of the following four classes of antibiotics
being used for at least 3 days within 3 months prior to the
date of the first blood culture positive for FRPa was
recorded: penicillins or cephalosporins, carbapenems, flu-
oroquinolones, and aminoglycosides.
Treatment and outcome
Appropriate antibiotic therapy was defined as any one of
antibiotic agents that was used for at least 3 days with
correct dosage subsequently proved to be effective in vitro
against the FRPa blood isolates. The time intervals between
collection of index FRPa blood culture and appropriate
antibiotic therapy were recorded. Empirical combination
therapy was defined as therapy for Gram-negative in-
fections with at least two classes of antimicrobial agents
commenced prior to the identification of the causative
microorganism and continued for at least 3 days regardless
of the antimicrobial susceptibility for FRPa. The all-cause
mortality rates of the cases at 15 days and 30 days were
recorded.
Statistical analysis
All statistical analyses were performed using SPSS for Win-
dows (version 18.0; SPSS Inc., Chicago, IL, USA). Categorical
variables were compared using c2 test or Fisher exact test,
as appropriate. Continuous variables were compared by
ManneWhitney U test. Variables with p < 0.1 in univariate
analysis were included in a multiple logistic regression
model using backward stepwise method to identify the riskfactors for 15-day and 30-day mortalities. Adjusted odds
ratio (OR) and 95% confidence interval (CI) were calculated.
The survival curve was plotted by the KaplaneMeier
method, and the log-rank test was used to compare uni-
variate survival distribution. All tests were two-tailed, and
p < 0.05 was considered significant.
Results
Patients and clinical characteristics
Between January 2006 and December 2011, 1323 non-
duplicated P. aeruginosa blood isolates were identified,
including 103 FRPa blood isolates. Finally, 78 adult patients
with FRPa bacteremia were included in the study, and their
demographic and clinical characteristics are shown in
Table 1. All of them had at least one characteristic symp-
tom and sign suggestive of systemic infection, and 74 pa-
tients (94.9%) had at least two characteristics. Of the 78
patients, 46 (59.0%) were men. The mean age was
72.2  14.1 years (range: 33e94 years). The most common
comorbid disease was hypertension (52.6%), followed by
solid-organ malignancy (38.5%) and diabetes mellitus
(33.3%). The mean interval between admission and the
sample date of the first FRPa-positive blood culture was
45.8  52.6 days (range: 0e227 days). Sixty-five patients
(83.3%) had nosocomial infections, and the other 13 pa-
tients (16.7%) had hospitalization within 2 months prior to
the FRPa bacteremia episode.
Sixty-five patients (83.3%) had CVC use, including 78.5%
(51/65) short-term use and 21.5% (14/65) long-term use.
Forty-six individuals (59%) had ventilator use, and 45 in-
dividuals (57.7%) stayed in the ICU when FRPa bacteremia
occurred. The mean Pittsburgh bacteremia score was
5.0  3.4, and the mean Charlson Comorbidity Index was
6.0  10.0. Thirty-six patients (46.2%) had primary
bacteremia, and the other 42 patients (53.8%) had the
identified sources of FRPa bacteremia. The most common
source of bacteremia was lower respiratory tract infection
(28/42, 66.7%), followed by urinary tract infection (11/42,
26.2%). Ten patients (12.8%) had FRPa bacteremia with
multiple sources, and 28 patients (35.9%) had polymicrobial
bacteremia. Forty-three patients (55.1%) had MDR FRPa
bacteremia.
As for prior antibiotics exposure within 3 months, 68
patients (87.2%) had the use of penicillins or cephalospo-
rins, followed by 36 individuals (46.2%) with carbapenems
use and 32 individuals (41.0%) with fluoroquinolones use.
Treatment and outcomes
A total of 18 patients (23.1%), 28 patients (35.9%), and 41
patients (52.6%) had appropriate antibiotic therapy within
24 hours, 48 hours, and 72 hours after the sample date of
the first positive FRPa blood culture, respectively. Anti-
pseudomonal carbapenems and antipseudomonal fluo-
roquinolones were the two most commonly used
appropriate antibiotics (both 23.1%), followed by amino-
glycosides (20.5%). Thirteen patients (16.7%) had the
empirical combination therapy. The most common co-
administered antimicrobial agent was aminoglycosides
Table 1 Clinical characteristics of 78 patients with
cefepime-resistant Pseudomonas aeruginosa bacteremia
Variables Value
Demographic parameters
Age, y 72.2  14.1
Male sex 46 (59.0)
Comorbid diseases
Hypertension 41 (52.6)
Diabetes mellitus 26 (33.3)
End-stage renal disease 23 (29.5)
Liver cirrhosis 12 (15.4)
Chronic pulmonary disease 9 (11.5)
Cerebral vascular accident 18 (23.1)
Solid-organ malignancy 30 (38.5)
Hematology malignancy 6 (7.7)
Clinical conditions
Interval between admission and the
sample date of first positive blood
culture for FRPa, day
45.8  52.6
Central venous catheter use 65 (83.3)
Short term 51 (65.4)
Long term 17 (21.8)
Ventilator use 46 (59.0)
Intensive care unit stay 45 (57.7)
Pittsburgh bacteremia score 5.0  3.4
Charlson Comorbidity Index 6.0  10.0
Sources of FRPa bacteremia
Primary 36 (46.2)
Lower respiratory tract 28 (35.9)
Urinary tract 11 (14.1)
Skin and soft tissues 7 (9.0)
Catheter-related bloodstream infection 5 (6.4)
Intra-abdominal infection 3 (3.8)
Multiple sources 10 (12.8)
Microbiology
Polymicrobial bacteremia 28 (35.9)
Multidrug-resistant P. aeruginosa 43 (55.1)
Prior antibiotics exposure within 3 mo
Penicillins or cephalosporins 68 (87.2)
Carbapenems 36 (46.2)
Fluoroquinolones 32 (41.0)
Aminoglycosides 14 (17.9)
Treatment
Appropriate antibiotic therapy within 24 h 18 (23.1)
Appropriate antibiotic therapy within 48 h 28 (35.9)
Appropriate antibiotic therapy within 72 h 41 (52.6)
With antipseudomonal penicillins or
cephalosporins
10 (12.8)
With antipseudomonal carbapenems 18 (23.1)
With antipseudomonal fluoroquinolones 18 (23.1)
With aminoglycosides 16 (20.5)
Combination therapy 13 (16.7)
With aminoglycosides 8 (10.3)
Other regimens 5 (6.4)
Outcome
15-d mortality 39 (50.0)
30-d mortality 51 (65.4)
Data are presented as n (%) or mean  standard deviation,
unless indicated specifically.
dZ day; FRPaZ cefepime-resistant P. aeruginosa; hZ hours;
mo Z months; y Z years.
Figure 1. Coresistance of 78 cefepime-resistant Pseudo-
monas aeruginosa blood isolates to the antipseudomonal
antimicrobial agents except cefepime. AN Z amikacin;
CAZ Z ceftazidime; CIP Z ciprofloxacin; GM Z gentamicin;
IPM Z imipenem; MEM Z meropenem; PIP Z piperacillin;
TZP Z piperacillinetazobactam.
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mortality was 65.4% (Table 1).
Coresistance of FRPa blood isolates
The coresistance to antipseudomonal agents other than
cefepime is shown in Fig. 1. The FRPa blood isolates in thisFigure 2. KaplaneMeier survival curve in patients with and
without appropriate antibiotic therapy within 72 hours after
diagnosis of cefepime-resistant Pseudomonas aeruginosa
bacteremia, with p Z 0.011 (by log-rank test).
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and the coresistance rates were high for ceftazidime
(78.2%) and piperacillin (87.2%). About half of the isolates
were simultaneously resistant to ciprofloxacin (55.1%) and
imipenemecilastatin (50%).Analyses of risk factors for 15- and 30-day mortality
of FRPa bacteremia
The cumulative survival rate at 30 days revealed that pa-
tients with appropriate antibiotic therapy within 72 hours
had a significantly higher survival rate than those without,
and the survival curves showed significant difference (48.8%
vs. 18.9%, p Z 0.011 by log-rank test; Fig. 2).
In univariate analysis for 15-day mortality (Table 2), the
deceased patients had a higher rate of ICU stay (71.8% vs.
43.6%, p Z 0.012), a higher Pittsburgh bacteremia scoreTable 2 Univariate and multivariate analyses of risk factors fo
ginosa bacteremia
Variables Deceased Survived
n Z 39 n Z 39
Demographic parameters
Age, y 71.64  15.48 72.79  12.
Male sex 24 (61.5) 22 (56.4)
Comorbid diseases
Hypertension 22 (56.4) 19 (48.7)
Diabetes mellitus 14 (35.9) 12 (30.8)
End-stage renal disease 15 (38.5) 8 (20.5)
Liver cirrhosis 8 (20.5) 4 (10.3)
Chronic pulmonary disease 5 (12.8) 4 (10.3)
Cerebral vascular accident 8 (20.5) 10 (25.6)
Solid-organ malignancy 12 (30.8) 18 (46.2)
Hematologic malignancy 2 (5.1) 4 (10.3)
Clinical conditions
Intensive care unit stay 28 (71.8) 17 (43.6)
Pittsburgh bacteremia score 6.26  3.55 3.69  2.83
Charlson Comorbidity Index 6.08  2.8 5.9  3.52
Source of FRPa bacteremia
Primary 15 (38.5) 21 (53.8)
Lower respiratory tract 18 (46.2) 10 (25.6)
Urinary tract 5 (12.8) 6 (15.4)
Skin and soft tissues 6 (15.4) 1 (2.6)
CRBSI 3 (7.7) 2 (5.1)
Intra-abdominal site 0 3(7.7)
Multiple sources 6 (15.4) 4 (10.3)
Microbiology
Polymicrobial bacteremia 17 (43.6) 11 (28.2)
MDR P. aeruginosa 19 (48.7) 24 (61.5)
Treatment
Appropriate antibiotic
therapy within 72 h
16 (41.0) 25 (64.1)
Combination therapy 4 (10.3) 9 (23.1)
With aminoglycosides 1 (2.6) 7 (17.9)
Other regimens 3 (7.7) 2 (5.1)
a All variables with p < 0.1 in univariate analysis were included in a
Data are presented as n (%) or mean  standard deviation, unless ind
CI Z confidence interval; CRBSI Z catheter-related bloodstream in
MDR Z multidrug resistant; OR Z odds ratio; y Z years.(6.3  3.6 vs. 3.7  2.8, p Z 0.001), and a lower rate of
appropriate antibiotic therapy within 72 hours (41.0% vs.
64.1%, pZ 0.041) when compared with those who survived.
In multivariate analysis, a higher Pittsburgh bacteremia
score was an independent risk factor for 15-day mortality
(adjusted OR: 1.293; 95% CI: 1.098e1.522; pZ 0.002), and
appropriate antibiotic therapy within 72 hours was an in-
dependent protecting factor (adjusted OR: 0.2367; 95% CI:
0.135e0.998; p Z 0.049).
In univariate analysis for 30-day mortality (Table 3), the
deceased patients also had a higher rate of ICU stay (68.6%
vs. 37.0%, pZ 0.007), a higher Pittsburgh bacteremia score
(5.7  3.5 vs. 3.6  2.9, p Z 0.007), and a lower rate of
appropriate antibiotic therapy within 72 hours (41.2% vs.
74.1%, pZ 0.006) when compared with those who survived.
In multivariate analysis, a higher Pittsburgh bacteremia
score was an independent risk factor for 30-day mortality
(adjusted OR: 1.261; 95% CI: 1.507e1.504; pZ 0.010), andr 15-day mortality of cefepime-resistant Pseudomonas aeru-
Univariate Multivariatea
p Adjusted OR 95% CI p
65 0.901
0.818
0.496
0.631
0.082
0.347
> 0.99
0.591
0.163
0.675
0.012
0.001 1.293 1.098e1.522 0.002
0.608
0.173
0.059
0.745
0.108
> 0.99
0.240
0.737
0.157
0.255
0.041 0.367 0.135e0.998 0.049
0.224
0.056
> 0.99
multivariate regression model using backward stepwise method.
icated specifically.
fection; FRPa Z cefepime-resistant P. aeruginosa; h Z hours;
Table 3 Univariate and multivariate analyses of risk factors for 30-day mortality of cefepime-resistant Pseudomonas aeru-
ginosa bacteremia
Variables Deceased Survived Univariate Multivariatea
n Z 51 n Z 27 p Adjusted OR 95% CI p
Demographic parameters
Age, y 72.5  15.2 71.6  11.8 0.610
Male sex 30 (58.8) 16 (59.3) 0.970
Comorbid diseases
Hypertension 28 (54.9) 13 (48.1) 0.570
Diabetes mellitus 18 (35.3) 8 (29.6) 0.614
End-stage renal disease 18 (35.3) 5 (18.5) 0.122
Liver cirrhosis 8 (15.7) 4 (14.8) 0.919
Chronic pulmonary disease 7 (13.7) 2 (7.4) 0.485
Cerebral vascular accident 11 (21.6) 7 (25.9) 0.664
Solid-organ malignancy 17 (33.3) 13 (48.1) 0.201
Hematologic malignancy 2 (3.9) 4 (14.8) 0.174
Clinical conditions
Intensive care unit stay 35 (68.6) 10 (37.0) 0.007
Pittsburgh bacteremia score 5.7  3.5 3.6  2.9 0.007 1.261 1.057e1.504 0.010
Charlson Comorbidity Index 6.3  3.4 5.4  2.7 0.401
Source of FRPa bacteremia
Primary 22 (43.1) 14 (51.9) 0.463
Lower respiratory tract 21 (41.2) 7 (25.9) 0.182
Urinary tract 6 (11.8) 5 (18.5) 0.415
Skin and soft tissues 7 (13.7) 0 (0.0) 0.089
CRBSI 3 (5.9) 2 (7.4) > 0.99
Intra-abdominal site 1 (2.0) 2 (7.4) 0.274
Multiple sources 7 (13.7) 3 (11.1) > 0.99
Microbiology
Polymicrobial bacteremia 21 (41.2) 7 (25.9) 0.182
MDR P. aeruginosa 25 (49.0) 18 (66.7) 0.136
Treatment
Appropriate antibiotic therapy
within 72 h
21 (41.2) 20 (74.1) 0.006 0.252 0.082e0.779 0.017
Combination therapy 6 (11.8) 7 (25.9) 0.110
With aminoglycosides 3 (5.9) 5 (18.5) 0.117
Other regimens 3 (5.9) 2 (7.4) > 0.99
a All variables with p < 0.1 in univariate analysis were included in a multivariate regression model using backward stepwise method.
Data are presented as n (%) or mean  standard deviation, unless indicated specifically.
CIZ confidence interval; CRBSIZ catheter-related bloodstream infection; FRPaZ cefepime-resistant P. aeruginosa; MDRZ multidrug
resistant; OR Z odds ratio; y Z years.
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dependent protecting factor (adjusted OR: 0.252; 95% CI:
0.082e0.779; p Z 0.017).Discussion
In this epidemiological survey, patients with FRPa bacter-
emia were aged with one or more comorbid illnesses. All
the FRPa bacteremia episodes were healthcare associated
or hospital acquired. The disease severity was high. Venti-
lator use and ICU stay were common. Without a comparison
group of patients with bacteremia caused by cefepime-
susceptible P. aeruginosa, it is hard to indicate these
characteristics were particularly associated with FRPa in
this study. However, these clinical characteristics had been
identified to be associated with FRPa infection or coloni-
zation in previous comparison studies. Akhabue et al9 hadrecognized that patients with FRPa were associated with
prior antibiotic use, ICU stay, transfer from another facility,
and multiple concurrent illnesses while comparing patients
with FRPa to those without. More than half of our FRPa
blood isolates were MDR P. aeruginosa. Previous studies also
reported that MDR P. aeruginosa bacteremia usually had a
nosocomial onset17 and was associated with a longer hos-
pital stay,17,18 mechanical ventilator use, and ICU stay.19,20
Akhabue et al9 also indicated that patients with FRPa
had a higher mortality rate than those without (20.2% vs.
13.2%, p Z 0.007), and FRPa bacteremia was an indepen-
dent risk factor for death (pZ 0.001). Our study focused on
patients with FRPa bacteremia, and further investigated
their risk factors for mortality. Our patients had a 30-day
mortality rate of 65.4%, which was higher than that in
previous studies on P. aeruginosa bacteremia (ranged from
18.4% to 29%).21e24 In risk factor analyses for 15-day and 30-
day mortalities, Pittsburgh bacteremia score, which was
Cefepime-resistant Pseudomonas aeruginosa bacteremia 181reflecting the high disease severity in our patient group,
stood out as an independent risk factor. This finding was
similar to that in previous studies for P. aeruginosa
bacteremia; critical illness and ICU admission were usually
associated with increased mortality in patients with such a
bacteremia.19,20,24 Either for 15-day or 30-day mortality,
appropriate antibiotic therapy within 72 hours was an in-
dependent protecting factor whereas the Pittsburgh
bacteremia score was included in multivariate analyses. In
other words, absence of appropriate antibiotic therapy
within 72 hours was also an independent risk factor for
mortality in patients with FRPa bacteremia.
Previous studies have shown the trends toward increased
mortality after inappropriate empirical antimicrobial
treatment for P. aeruginosa bloodstream infections.25e27 In
a retrospective cohort study of 305 patients with P. aeru-
ginosa bloodstream infection, the hospital mortality rate
was statistically higher for patients with inappropriate
initial antimicrobial treatment compared with appropriate
initial treatment (30.7% vs. 17.8%; p Z 0.018).25 Inappro-
priate initial antimicrobial treatment was defined as the
absence of an agent given with in vitro activity as deter-
mined by susceptibility testing, and was identified as an
independent determinant of hospital mortality (adjusted
OR: 2.04; 95% CI: 1.42e2.92; p Z 0.048).25
In another retrospective cohort of 100 patients with P.
aeruginosa bacteremia, the most significant delay break
point to define the risk of 30-day mortality was 52 hours.27
Patients receiving appropriate therapy over 52 hours after
the index P. aeruginosa blood culture collection had a
greater than twofold increase in 30-day mortality
compared with those receiving appropriate therapy within
52 hours of index culture collection (43.8% vs. 19.2%;
pZ 0.008). Besides, antibiotic resistance to three or more
drug classes was the most important determinant of
delayed appropriate therapy (adjusted OR: 4.6; 95% CI:
1.9e11.2; p Z 0.001). MDR might decrease the likelihood
of receiving appropriate empirical antibiotics timely. In our
study, only about half the patients had appropriate anti-
biotic therapy in the first 3 days of FRPa bacteremia, and
more than half of the FRPa blood isolates were MDR
P. aeruginosa.
Combination antimicrobial therapy for P. aeruginosa in-
fections is still a matter for debate. Empirical combination
therapy had been suggested to minimize inappropriate
initial antimicrobial treatment in patients with P. aerugi-
nosa bacteremia.25,28 In one study for P. aeruginosa
bloodstream infection, appropriate initial antimicrobial
treatment was administered statistically more often among
patients receiving empirical combination antimicrobial
treatment for Gram-negative bacteria compared with
empirical monotherapy (79.4% vs. 65.5%; p Z 0.011).25
However, the statistic difference between mortality rate
and empirical combination therapy was not shown in the
same study.25 In a recent prospective cohort study in Bar-
celona, both empirical and definite combination antimi-
crobial therapy did not reduce the mortality risk compared
with single-drug therapy in P. aeruginosa bloodstream in-
fections.29 Similar results were obtained in the study by
Bowers et al.30 In our cases, empirical combination therapy
was uncommon (only 16.7%), the small case numbers might
limit a comprehensive analysis to recognize the relationshipbetween combination therapy and mortality. Further
expanded studies may help us to clarify the role of com-
bination therapy in FRPa bacteremia.
This study had several limitations. For the nature of
retrospective design, the diagnosis and management of
sepsis and antibiotic choice were based on individual cli-
nicians’ opinions. Our data were collected from a single
site, so institutional differences in prescribing patterns,
antibiotic formularies, and patient populations may affect
the applicability of our results to other institutions. Finally,
molecular types of the FRPa isolates were not identified,
and resistance mechanisms were not investigated.
Different genotypes of FRPa might have differences in
clinical characteristics and outcomes.
In conclusion, patients with FRPa bacteremia had high
disease severity and complicated clinical conditions. High
Pittsburgh bacteremia score and absence of appropriate
antimicrobial therapy within 72 hours were two indepen-
dent risk factors for mortality of FRPa bacteremia. Further
study should aim on active surveillance with the change of
P. aeruginosa susceptibility profile for adjustment of
adequate empirical antimicrobial therapy regimens to
improve patients’ outcome.Conflicts of interest
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